+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 85Years
All Genders
ID06825702

Study of Safety, Tolerability, and Efficacy of Intravitreal KIO-104 for Adults with Macular Edema including Multiple Dose Regimens

Led by Kiora Pharmaceuticals, Inc. · Updated on 2026-09-09

28

Participants Needed

6

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of KIO-104, an investigational drug given by injection into the eye, for adults with macular edema. This open-label, Phase 2 study aims to assess KIO-104 in participants diagnosed with macular edema caused by conditions such as non-infectious uveitis, retinal vein occlusion, diabetic retinopathy, or cataract surgery. The study is sponsored by Kiora Pharmaceuticals, Inc. and involves multiple treatment groups to explore different doses and dosing schedules. The study consists of two parts. Part A tests up to three doses of KIO-104 given every two weeks in two dose levels low and high. Part B evaluates up to three doses of KIO-104 selected from Part A at either two-week or four-week intervals. Participants receive the drug directly into the study eye via intravitreal injection according to their assigned dose and schedule. The study groups include low-dose and high-dose KIO-104 given every two weeks and low- or high-dose given every four weeks. Participants will attend study visits during treatment to receive injections and complete assessments. Researchers will measure safety and tolerability over about 23 months. Evaluations include eye exams, visual acuity tests, and imaging to assess macular thickness. Participants must follow study instructions, avoid certain medications, and adhere to contraception requirements. The total participation time spans screening through the treatment and follow-up periods, with close monitoring of outcomes and any side effects.

CONDITIONS

Brief Title

Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

Research Team

C

Claudia Gregorio-King

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here